Alerts will be sent to your verified email
Verify EmailEMCURE
Emcure Pharma
|
Wockhardt
|
Piramal Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
7.3 % | 10.6 % | 15.43 % |
US DMF Filings
|
102.0 . | n/a | n/a |
R&D as a % of Total Sales
|
4.66 % | 4.6 % | 0.14 % |
Financials
|
|||
5 yr Average ROE
|
18.62 % | -3.51 % | 3.82 % |
5yr average Equity Multiplier
|
2.84 | 2.02 | 1.94 |
5yr Average Asset Turnover Ratio
|
0.91 | 0.39 | 0.55 |
5yr Avg Net Profit Margin
|
7.16 % | -4.28 % | 3.51 % |
Price to Book
|
5.81 | 6.01 | 3.12 |
P/E
|
37.94 | 0.0 | 258.34 |
5yr Avg Cash Conversion Cycle
|
-21.19 Days | -94.15 Days | -19.3 Days |
Inventory Days
|
82.48 Days | 61.29 Days | 70.13 Days |
Days Receivable
|
94.32 Days | 60.36 Days | 77.05 Days |
Days Payable
|
169.53 Days | 251.45 Days | 159.9 Days |
5yr Average Interest Coverage Ratio
|
4.17 | -0.43 | 2.86 |
5yr Avg ROCE
|
26.51 % | -0.28 % | 6.75 % |
5yr Avg Operating Profit Margin
|
19.04 % | 5.03 % | 15.15 % |
5 yr average Debt to Equity
|
0.95 | 0.56 | 0.62 |
5yr CAGR Net Profit
|
42.9 % | n/a | -35.79 % |
5yr Average Return on Assets
|
6.6 % | -1.79 % | 2.03 % |
Shareholdings
|
|||
Promoter Holding
|
77.91 % | 49.09 % | 34.86 % |
Share Pledged by Promoters
|
0.04 % | 15.64 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.17 % | -16.66 % | 0.07 % |
Change in Mutual Fund Holding (3 Yrs)
|
-0.96 % | 7.99 % | 11.78 % |
Emcure Pharma
|
Wockhardt
|
Piramal Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
Asset Break-Up - Geography Wise
|
Asset Break-Up - Geography Wise
|
-
|
-
|